Related references
Note: Only part of the references are listed.Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment
Binlong Chen et al.
THERANOSTICS (2017)
Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer
Yuan Sheng et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents
Huining He et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Targeting HER2 for the Treatment of Breast Cancer
Mothaffar F. Rimawi et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Phosphatidylinositol-3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro
Dmitriy Smolensky et al.
BMC CANCER (2015)
Acid-Sensitive Peptide-Conjugated Doxorubicin Mediates the Lysosomal Pathway of Apoptosis and Reverses Drug Resistance in Breast Cancer
Yuan Sheng et al.
MOLECULAR PHARMACEUTICS (2015)
Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms
Luc Rochette et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Neuronal Differentiation of Human Mesenchymal Stem Cells Using Exosomes Derived from Differentiating Neuronal Cells
Yuji S. Takeda et al.
PLOS ONE (2015)
Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs
Lin Zhu et al.
BIOMATERIALS (2014)
Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion
Y. Hassona et al.
BRITISH JOURNAL OF CANCER (2014)
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Vladimir P. Torchilin
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma
Zorica Milosevic et al.
TRANSLATIONAL RESEARCH (2014)
Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systems
Chie Kojima et al.
ACTA BIOMATERIALIA (2013)
HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
Susan Dent et al.
CANCER TREATMENT REVIEWS (2013)
Novel Peptide-Doxorubucin Conjugates for Targeting Breast Cancer Cells Including the Multidrug Resistant Cells
Rania Soudy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
SUBCELLULAR QUANTIFICATION OF DOXORUBICIN AND ITS METABOLITE IN CULTURED HUMAN LEUKEMIA CELLS USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY
Jinhui Xu et al.
ANALYTICAL LETTERS (2012)
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
Amy D. Guertin et al.
CANCER CELL INTERNATIONAL (2012)
Multi-Target Drugs: The Trend of Drug Research and Development
Jin-Jian Lu et al.
PLOS ONE (2012)
Trastuzumab (Herceptin)
J. J. Gemmete et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effect
Pascal Schlage et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Tumor Targeting of MMP-2/9 Activatable Cell-Penetrating Imaging Probes Is Caused by Tumor-Independent Activation
Sander M. J. van Duijnhoven et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Treatment of HER2-overexpressing breast cancer
J. Baselga
ANNALS OF ONCOLOGY (2010)
The role of HER2 in cancer therapy and targeted drug delivery
Wanyi Tai et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise
Karen Y. Wonders et al.
INTEGRATIVE CANCER THERAPIES (2009)
The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
Yutaka Tokuda et al.
BREAST CANCER (2009)
Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates
Song Li et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide
M Tan et al.
CANCER RESEARCH (2006)
Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression
S Jodele et al.
CANCER AND METASTASIS REVIEWS (2006)
A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells
VR Fantin et al.
CANCER RESEARCH (2005)
From magic bullets to designed multiple ligands
R Morphy et al.
DRUG DISCOVERY TODAY (2004)
Ethanol-induced in vitro invasion of breast cancer cells:: The contribution of MMP-2 by fibroblasts
MM Aye et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Biologic and therapeutic role of HER2 in cancer
S Ménard et al.
ONCOGENE (2003)
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition
XF Le et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Therapeutic cancer targeting peptides
OH Aina et al.
BIOPOLYMERS (2002)
Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis
A Berezov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari et al.
ONCOGENE (2000)
Rationally designed anti-HER2/neu peptide mimetic disables p185HER2/neu tyrosine kinases in vitro and in vivo
BW Park et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
